- Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US.JAMA Netw Open. 2021; 4: e216139
- The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.Diabetologia. 2021; 64: 349-360
- Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: a retrospective cohort analysis.PLoS Med. 2019; 16: e1002942
Financial Disclosure: D.Z.I.C has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and Novo-Nordisk. S.E.R.‘s institution has received funding for clinical research from NIDDK, Bayer Healthcare, and AstraZeneca. Dr Rosas has participated in scientific advisory boards for Reata, Relypsa, Astra Zeneca, and Bayer Healthcare.
Support: D.Z.I.C. is supported by a Department of Medicine, University of Toronto Merit Award and receives support from the CIHR , Diabetes Canada and the Heart and Stroke Richard Lewar Center of Excellence. S.E.R. is an employee of the Joslin Diabetes Center.